At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
News|Poll|July 7, 2014
A 22-Year-Old Patient Presents With Arm Nodule
Author(s)Cesar A. Moran, MD
A 22-year-old man presents with a firm, painless nodule on his arm that is approximately 1 cm in size. No discoloration of the skin is identified. What is your diagnosis?
Advertisement
A 22-year-old man presents with a firm, painless nodule on his arm that is approximately 1 cm in size. No discoloration of the skin is identified.
What is your diagnosis?
Advertisement
Related to this article
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5